高流量氧疗与常规氧疗对重症COVID-19患者有创机械通气及临床恢复的影响:一项随机临床试验
这项在哥伦比亚3家医院急诊和ICU开展的随机开放标签临床试验,纳入220例因COVID-19导致呼吸窘迫且PaO2/FiO2低于200的成人患者,比较经鼻导管高流量氧疗与常规氧疗。结果显示高流量氧疗组插管率34.3% vs 常规氧疗组51.0%(HR 0.62,95%CI 0.39-0.96,P=0.03),28天内临床恢复中位时间11天 vs 14天(HR 1.39,95%CI 1.00-1.92,P=0.047)。
要点
- 重症COVID-19患者使用经鼻导管高流量氧疗较常规低流量氧疗显著降低插管需求。
- 高流量氧疗组28天内临床恢复中位时间11天,常规氧疗组为14天。
- 高流量氧疗组疑似细菌性肺炎13.1%、菌血症7.1%,常规氧疗组分别为17.0%、11.0%。
核心结论
- 在重症COVID-19患者中,与常规低流量氧疗相比,使用经鼻导管高流量氧疗显著降低了机械通气支持需求和临床恢复时间。
研究设计与样本
- 随机、开放标签临床试验,在哥伦比亚3家医院的急诊和重症监护病房开展。
- 2020年8月至2021年1月随机纳入220例因COVID-19导致呼吸窘迫且动脉血氧分压与吸入氧浓度比值低于200的成人患者,末次随访为2021年2月10日。
- 患者随机接受经鼻导管高流量氧疗(n=109)或常规氧疗(n=111)。
- 主要结局为插管需求和至第28天临床恢复时间,后者采用7分类序数量表评估(范围1-7,评分越高表示状况越差)。
- 治疗效果采用Cox比例风险模型计算,校正低氧血症严重程度、年龄和合并症。
主要发现
- 220例随机患者中199例纳入分析(中位年龄60岁;女性65例[32.7%])。
- 高流量氧疗组插管34例(34.3%),常规氧疗组插管51例(51.0%)(HR 0.62;95%CI 0.39-0.96;P=0.03)。
- 28天内临床恢复中位时间在高流量氧疗组为11天(IQR 9-14),常规氧疗组为14天(IQR 11-19)(HR 1.39;95%CI 1.00-1.92;P=0.047)。
- 疑似细菌性肺炎在高流量氧疗组发生13例(13.1%),常规氧疗组17例(17.0%);菌血症分别检出7例(7.1%) vs 11例(11.0%)。
临床怎么用
- 原文结论指出,在重症COVID-19患者中,与常规低流量氧疗相比,使用经鼻导管高流量氧疗显著降低了机械通气支持需求和临床恢复时间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The effect of high-flow oxygen therapy vs conventional oxygen therapy has not been established in the setting of severe COVID-19. OBJECTIVE: To determine the effect of high-flow oxygen therapy through a nasal cannula compared with conventional oxygen therapy on need for endotracheal intubation and clinical recovery in severe COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label clinical trial conducted in emergency and intensive care units in 3 hospitals in Colombia. A total of 220 adults with respiratory distress and a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen of less than 200 due to COVID-19 were randomized from August 2020 to January 2021, with last follow-up on February 10, 2021. INTERVENTIONS: Patients were randomly assigned to receive high-flow oxygen through a nasal cannula (n = 109) or conventional oxygen therapy (n = 111). MAIN OUTCOMES AND MEASURES: The co-primary outcomes were need for intubation and time to clinical recovery until day 28 as assessed by a 7-category ordinal scale (range, 1-7, with higher scores indicating a worse condition). Effects of treatments were calculated with a Cox proportional hazards model adjusted for hypoxemia severity, age, and comorbidities. RESULTS: Among 220 randomized patients, 199 were included in the analysis (median age, 60 years; n = 65 women [32.7%]). Intubation occurred in 34 (34.3%) randomized to high-flow oxygen therapy and in 51 (51.0%) randomized to conventional oxygen therapy (hazard ratio, 0.62; 95% CI, 0.39-0.96; P = .03). The median time to clinical recovery within 28 days was 11 (IQR, 9-14) days in patients randomized to high-flow oxygen therapy vs 14 (IQR, 11-19) days in those randomized to conventional oxygen therapy (hazard ratio, 1.39; 95% CI, 1.00-1.92; P = .047). Suspected bacterial pneumonia occurred in 13 patients (13.1%) randomized to high-flow oxygen and in 17 (17.0%) of those randomized to conventional oxygen therapy, while bacteremia was detected in 7 (7.1%) vs 11 (11.0%), respectively. CONCLUSIONS AND RELEVANCE: Among patients with severe COVID-19, use of high-flow oxygen through a nasal cannula significantly decreased need for mechanical ventilation support and time to clinical recovery compared with conventional low-flow oxygen therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04609462.
引用
- Ospina-Tascón GA, Calderón-Tapia LE, García AF, et al. Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021. PMID: 34874419. doi:10.1001/jama.2021.20714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。